Aktis Oncology starts second Phase 1b trial for AKY-2519
Aktis Oncology said it initiated a second Phase 1b clinical trial for AKY-2519, a miniprotein radioconjugate targeting B7-H3.
Aktis Oncology said it initiated a second Phase 1b clinical trial for AKY-2519, a miniprotein radioconjugate targeting B7-H3.